Related Experiment Videos
Dopamine systems in human immunodeficiency virus-associated dementia
O L Lopez1, G Smith, C C Meltzer
1Department of Neurology, University of Pittsburgh School of Medicine, Pennsylvania, USA.
Neuropsychiatry, Neuropsychology, and Behavioral Neurology
|August 24, 1999
Summary
Human immunodeficiency virus (HIV)-associated dementia (HAD) involves dopamine system dysfunction, impacting cognitive and motor functions. Understanding this neurobiology is key for developing treatments for HAD.
Area of Science:
- Neurobiology
- Neurovirology
- Neuroimmunology
Background:
- Human immunodeficiency virus (HIV) often affects subcortical brain regions, including the basal ganglia.
- HIV-associated dementia (HAD) symptoms resemble those of frontal-striatal dysfunction, characteristic of subcortical dementias.
Purpose of the Study:
- To update the understanding of the neurobiologic underpinnings of HIV-associated dementia (HAD).
- To explore the connection between dopamine (DA) system dysfunction and the behavioral symptoms of HAD.
Main Methods:
- Review of neurobiologic investigations into HIV-associated dementia.
- Analysis of cerebrospinal fluid (CSF) neurotransmitter levels and neuropathologic findings.
Main Results:
- Dopamine neuron damage occurs early in HIV infection, with decreased CSF DA levels.
- Patients with HAD show reduced homovanillic acid (a DA metabolite) but preserved other neurotransmitters, indicating DA neuron loss.
- Neuropathology reveals neuronal loss in the globus pallidus, with less severe neocortical involvement. Extrapyramidal signs and hypersensitivity to DA antagonists are common.
Conclusions:
- Dopamine system dysfunction is critical to the clinical presentation of HIV infection and HAD.
- The specific reasons for the dopamine system's vulnerability to HIV remain unclear.
- Further understanding is crucial for developing neuroprotective agents and novel therapies for HAD-related psychiatric symptoms.